SEC Form 4 · accession 0001140361-16-056186
Asterias Biotherapeutics, Inc. · AST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
BIOTIME INC
10% Owner
Period of report
Feb 29, 2016
Accepted (ET)
Mar 2, 2016 · 9:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001572552
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Series A Common StockF1 | Feb 29, 2016 | J | 75,771 | — | D | 21,747,569 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to purchase Series A Common StockF1 | $5.00 | Feb 29, 2016 | J | 3,150,000 | D | Oct 1, 2013 | Sep 30, 2016 | Series A Common Stock | 3,150,000 | 0 | D |
Explanation of responses
- F1The Reporting Person transferred to the Issuer 75,771 shares Series A Common Stock of the Issuer and warrants to purchase 3,150,000 shares of Series A Common Stock of the Issuer in connection with a (a) the cross-licensing and sublicensing of certain patent rights and technology between the Issuer, the Reporting Person and another subsidiary of the Reporting Person, and (b) the transfer of shares of capital stock of certain subsidiaries of the Reporting Person from the Issuer to the Reporting Person. The shares of Series A Common Stock were valued at $3.07 per share, and the warrants were valued at $2,906,883, by the Reporting Person and the Issuer for purposes of the transaction.